a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

被引：0

作者：

Koenig, Kristin L. ^{[1
]}

Brame, Colin ^{[2
]}

Sher, Steven ^{[1
]}

Beaver, Larry ^{[1
]}

Cempre, Casey B. ^{[1
]}

Williams, Katie ^{[1
]}

Purcell, Matthew ^{[2
]}

Harrington, Bonnie ^{[3
]}

Chen, Yi ^{[4
]}

Tan, Felai ^{[4
]}

Anthony, Stephen P. ^{[4
]}

Chen, Yu ^{[4
]}

Shen, Yue ^{[4
]}

Byrd, John C. ^{[5
]}

Lapalombella, Rosa ^{[6
]}

机构：

[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA

[2] Ohio State Univ, Columbus, OH USA

[3] Charles River Labs, Wilmington, NC USA

[4] Newave Pharmaceut Inc, Pleasanton, CA USA

[5] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[6] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170578

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LP-118

引用

页码：9068 / 9069

页数：2

共 50 条

[31] Association of bcl-2, bax, bcl-xL and inteuleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
Stoetzer, OJ
Nussler, V
Darsow, M
Gullis, E
PelkaFleischer, R
Scheel, U
Wilmanns, W
LEUKEMIA, 1996, 10 : S18 - S22
[32] Targeting Bcl-2 in acute myeloid leukemia cells.
Simms-Waldrip, T
Hernandez, J
Shankar, D
Moore, TB
Sakamoto, KM
JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S105 - S105
[33] BCL-2 inhibition in acute myeloid leukemia: resistance and combinations
Tatarata, Qi Zhang
Wang, Zhe
Konopleva, Marina
EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (12) : 935 - 946
[34] BCL-2 ONCOPROTEIN EXPRESSION IN ACUTE MYELOID-LEUKEMIA
BENSI, L
LONGO, R
VECCHI, A
MESSORA, C
GARAGNANI, L
BERNARDI, S
TAMASSIA, MG
SACCHI, S
HAEMATOLOGICA, 1995, 80 (02) : 98 - 102
[35] High levels of bcl-2 protein do not affect prognosis in acute myeloid leukemia (AML)
DelPoeta, G
Venditti, A
Stasi, R
Aronica, G
Bruno, A
Buccisano, F
Cox, C
Maffei, L
Caravita, T
Suppo, G
Piccioni, D
Santinelli, S
Masi, M
Tribalto, M
Papa, G
Amadori, S
BLOOD, 1995, 86 (10) : 151 - 151
[36] BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML
Ossenkoppele, Gert
Vyas, Paresh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (30) : 3461 - +
[37] Dual Sphingosine Kinase and Bcl-2 Inhibition Exhibits Synergistic Cell Death in Acute Myeloid Leukemia
Lewis, Alexander C.
D'Andrea, Richard
Powell, Jason A.
Pitson, Stuart M.
BLOOD, 2017, 130
[38] A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)
Ando, Hidenori
Murakami, Yuta
Eshima, Kiyoshi
Ishida, Tatsuhiro
CANCER REPORTS, 2022, 5 (03)
[39] The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Chen, Jun
Jin, Sha
Abraham, Vivek
Huang, Xiaoli
Liu, Bernard
Mitten, Michael J.
Nimmer, Paul
Lin, Xiaoyu
Smith, Morey
Shen, Yu
Shoemaker, Alexander R.
Tahir, Stephen K.
Zhang, Haichao
Ackler, Scott L.
Rosenberg, Saul H.
Maecker, Heather
Sampath, Deepak
Leverson, Joel D.
Tse, Chris
Elmore, Steven W.
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2340 - 2349
[40] Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Tao, Zhi-Fu
Hasvold, Lisa
Wang, Le
Wang, Xilu
Petros, Andrew M.
Park, Chang H.
Boghaert, Erwin R.
Catron, Nathaniel D.
Chen, Jun
Colman, Peter M.
Czabotar, Peter E.
Deshayes, Kurt
Fairbrother, Wayne J.
Flygare, John A.
Hymowitz, Sarah G.
Jin, Sha
Judge, Russell A.
Koehler, Michael F. T.
Kovar, Peter J.
Lessene, Guillaume
Mitten, Michael J.
Ndubaku, Chudi O.
Nimmer, Paul
Purkey, Hans E.
Oleksijew, Anatol
Phillips, Darren C.
Sleebs, Brad E.
Smith, Brian J.
Smith, Morey L.
Tahir, Stephen K.
Watson, Keith G.
Xiao, Yu
Xue, John
Zhang, Haichao
Zobel, Kerry
Rosenberg, Saul H.
Tse, Chris
Leverson, Joel D.
Elmore, Steven W.
Souers, Andrew J.
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (10): : 1088 - 1093

← 1 2 3 4 5 →